Drug intelligence / Profile preview

nivolumab + cabiralizumab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Nivolumab + cabiralizumab is a combination immunotherapy approach that pairs two distinct mechanisms of action. Nivolumab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, thereby enhancing T-cell function. Cabiralizumab is a CSF1R (Colony Stimulating Factor 1 Receptor) inhibitor that targets tumor-associated macrophages (TAMs). The combination aims to overcome resistance to PD-1/PD-L1 inhibitors by simultaneously enhancing T-cell activity and reducing immunosuppressive macrophages in the tumor microenvironment.

Brand names: Opdivo (for nivolumab)
Other names: cabiralizumab + nivolumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on nivolumab + cabiralizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nivolumab + cabiralizumab.

Explore the full profile